| Telix Pharmaceuticals (US) Inc |
74725010025 |
Illuccix (kit for the preparation of gallium Ga 68) - produced from a cyclotron and purified via GE FASTlab™ or Eckert & Ziegler GalliaPharm® Ge 68/Ga-68 generator gozetotide injection |
2022-04-08 |
4700.0000 |
Telix will market Illuccix® through a variety of channels, including sales conversations with health care professionals, digital banners, email marketing, patient education, professional associations, trade shows, and public relations.
Telix participates in Medicaid and agrees to provide outpatient drugs to 340B covered entities at significantly reduced prices. |
None |
170000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Telix Pharmaceuticals (US) Inc |
74725010064 |
Illuccix (kit for the preparation of gallium Ga 68) - produced from an IRE Galli Eo® Ge 68/Ga-68 generator gozetotide injection - |
2022-04-08 |
4700.0000 |
Telix will market Illuccix® through a variety of channels, including sales conversations with health care professionals, digital banners, email marketing, patient education, professional associations, trade shows, and public relations.
Telix participates in Medicaid and agrees to provide outpatient drugs to 340B covered entities at significantly reduced prices. |
None |
170000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Teva Pharmaceuticals USA |
00480124328 |
LENALIDOMIDE CAPSULE 10MG 28 |
2022-03-03 |
20157.3600 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 10,310 prescriptions per month (across all dosage strengths), based on historic IQVIA data, although research suggests that there are as many as 70,000 patients in the US whose conditions match the product’s approved indications and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed this product, in partnership with Natco Pharma. |
None |
| Teva Pharmaceuticals USA |
00480124421 |
LENALIDOMIDE CAPSULE 15MG 21 |
2022-03-03 |
15118.0400 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 10,310 prescriptions per month (across all dosage strengths), based on historic IQVIA data, although research suggests that there are as many as 70,000 patients in the US whose conditions match the product’s approved indications and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed this product, in partnership with Natco Pharma. |
None |
| Teva Pharmaceuticals USA |
00480124621 |
LENALIDOMIDE CAPSULE 25MG 21 |
2022-03-03 |
15118.0400 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 10,310 prescriptions per month (across all dosage strengths), based on historic IQVIA data, although research suggests that there are as many as 70,000 patients in the US whose conditions match the product’s approved indications and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed this product, in partnership with Natco Pharma. |
None |
| Teva Pharmaceuticals USA |
00480124228 |
LENALIDOMIDE CAPSULE 5MG 28 |
2022-03-03 |
20157.3600 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 10,310 prescriptions per month (across all dosage strengths), based on historic IQVIA data, although research suggests that there are as many as 70,000 patients in the US whose conditions match the product’s approved indications and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed this product, in partnership with Natco Pharma. |
None |
| Teva Pharmaceuticals USA |
00480943589 |
Diclofenac Potassium Caps 25mg 120 |
2022-03-24 |
1609.1100 |
None |
1 |
12000000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 1,243 prescriptions per month, based on historic IQVIA data, although research suggests that there are as many as 12,000,000 patients in the US whose conditions match the product’s approved indications and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed this product, in partnership with Bionpharma Inc. |
None |
| Teva Pharmaceuticals USA |
00480361087 |
PIRFENIDONE TABLETS 267MG 270 |
2022-05-11 |
7147.4100 |
None |
1 |
140000 |
None |
1 |
None |
None |
None |
None |
Estimated average of up to 4,708 prescriptions per month (across both dosage strengths), based on historic IQVIA data, although research suggests that as many as 140,000 Americans suffer from the condition that this product is indicated to treat. Acquisition fields left blank; Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00480361198 |
PIRFENIDONE TABLETS 801MG 90 |
2022-05-11 |
7147.4100 |
None |
1 |
140000 |
None |
1 |
None |
None |
None |
None |
Estimated average of up to 4,708 prescriptions per month (across both dosage strengths), based on historic IQVIA data, although research suggests that as many as 140,000 Americans suffer from the condition that this product is indicated to treat. Acquisition fields left blank; Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00480451501 |
PEMETREXED INJECTION 1 G/40 ML 1 |
2022-05-31 |
6849.3300 |
None |
1 |
51000 |
None |
None |
None |
None |
None |
None |
Although Teva launched this NDC at a WAC of $6,849.33, it subsequently lowered the WAC to $1,882.77.
Estimated average of 116 prescriptions per month (across both dosage strengths), based on historic IQVIA data and related internal forecasting, although research suggests that as many as 51,000 Americans may be eligible to take this product, based on its approved indications. Acquisition fields left blank; Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00480451401 |
PEMETREXED INJECTION 500 MG/20 ML 1 |
2022-05-31 |
3424.6700 |
None |
1 |
51000 |
None |
None |
None |
None |
None |
None |
Although Teva launched this NDC at a WAC of $3,424.67, it subsequently lowered the WAC to $990.93.
Estimated average of 116 prescriptions per month (across both dosage strengths), based on historic IQVIA data and related internal forecasting, although research suggests that as many as 51,000 Americans may be eligible to take this product, based on its approved indications. Acquisition fields left blank; Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00480449056 |
TASIMELTEON CAPSULE 20MG 30 |
2022-12-29 |
20570.9600 |
None |
1 |
90000 |
None |
None |
None |
None |
None |
None |
Research suggests that there are as many as 90,000 patients in the US whose condition matches the product’s approved indication and, thus, are candidates to take the product. Acquisition fields left blank; Teva developed the product. |
None |
| Tolmar Inc |
69087015812 |
Jatenza, 158 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle |
2022-10-28 |
962.6400 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers, patients, and caregivers about the approved indication, efficacy and safety data contained within the medicine's FDA approved label. Generally, Tolmar markets in the US at medical conferences in the urology, endocrinology, and general medicine community, as well as promoting to appropriate healthcare professionals, patients, and caregivers |
None |
2361 |
None |
None |
2022-10-27 |
7500000.0000 |
None |
None |
prices are for 120 tabs. |
None |
| Tolmar Inc |
69087019812 |
Jatenza, 198 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle |
2022-10-28 |
962.6400 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers, patients, and caregivers about the approved indication, efficacy and safety data contained within the medicine's FDA approved label. Generally, Tolmar markets in the US at medical conferences in the urology, endocrinology, and general medicine community, as well as promoting to appropriate healthcare professionals, patients, and caregivers |
None |
2361 |
None |
None |
2022-10-27 |
7500000.0000 |
None |
None |
prices are for 120 tabs. |
None |
| Tolmar Inc |
69087023712 |
Jatenza, 237 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle |
2022-10-28 |
1925.2600 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers, patients, and caregivers about the approved indication, efficacy and safety data contained within the medicine's FDA approved label. Generally, Tolmar markets in the US at medical conferences in the urology, endocrinology, and general medicine community, as well as promoting to appropriate healthcare professionals, patients, and caregivers |
None |
2361 |
None |
None |
2022-10-27 |
7500000.0000 |
None |
None |
prices are for 120 tabs. |
None |
| TruPharma, LLC |
52817072005 |
Apomorphine Hydrochloride Injection, 30mg/3mL (10mg/mL), 5-Count |
2022-03-01 |
5207.8500 |
This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only. |
None |
1500 |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=588 |
| TWi Pharmaceuticals USA, Inc. |
24979071051 |
Paclitaxel Protein-Bound Particles for Injectable Suspension 100mg, vial |
2022-04-07 |
1422.0500 |
Selling to hospitals and clinics as they represent 98% of the market.
Generic product discounted between 10-15% of brand product list price. |
None |
32000 |
None |
None |
2022-04-01 |
None |
1 |
None |
None |
None |
| TWi Pharmaceuticals USA, Inc. |
24979071544 |
Sorafenib 200mg 120ct |
2022-12-28 |
15000.0000 |
Sold as a low volume generic in a limited competition environment. |
None |
552 |
None |
None |
None |
None |
None |
None |
None |
None |